Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Anthony A Portale"'
Autor:
Karine Briot, Rachel K Crowley, Maria Luisa Brandi, Stuart H Ralston, Han-Wook Yoo, Peter Kamenický, Takuo Kubota, Nobuaki Ito, Martine Cohen-Solal, Richard Keen, Angela Williams, Muhammad K Javaid, Hiroyuki Tanaka, Robin H Lachmann, Karl Insogna, Richard Eastell, Yasuhiro Takeuchi, Anthony A Portale, Thomas O Carpenter, Hae Ii Cheong, Yasuo Imanishi, Steven Ing, Suzanne Jan de Beur, Farzana Perwad, Pisit Pitukcheewanont, Thomas J Weber, Annabel Nixon, Mark Nixon, Erik A Imel
Publikováno v:
RMD Open, Vol 7, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/1583f1afe5a54ea596b4387156690961
Autor:
Anthony A Portale, Martin Y H Zhang, Valentin David, Aline Martin, Yan Jiao, Weikuan Gu, Farzana Perwad
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0142924 (2015)
Fibroblast growth factor 23 (FGF23) is a potent regulator of phosphate (Pi) and vitamin D homeostasis. The transcription factor, early growth response 1 (egr-1), is a biomarker for FGF23-induced activation of the ERK1/2 signaling pathway. We have sho
Externí odkaz:
https://doaj.org/article/ef41c5028d2e46ddab769e37198c75ab
Autor:
Ankanee Chanakul, Martin Y H Zhang, Andrew Louw, Harvey J Armbrecht, Walter L Miller, Anthony A Portale, Farzana Perwad
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e72816 (2013)
The mitochondrial enzyme 25-hydroxyvitamin D 1α-hydroxylase, which is encoded by the CYP27B1 gene, converts 25OHD to the biological active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D). Renal 1α-hydroxylase activity is the principal deter
Externí odkaz:
https://doaj.org/article/b8cf89b9e6ee4244a51a3976bb54e96b
Autor:
Thomas J Weber, Erik A Imel, Thomas O Carpenter, Munro Peacock, Anthony A Portale, Joel Hetzer, J Lawrence Merritt, Karl Insogna
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 108:155-165
Context Burosumab was developed as a treatment option for patients with the rare, lifelong, chronically debilitating, genetic bone disease X-linked hypophosphatemia (XLH). Objective Collect additional information on the safety, immunogenicity, and cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6fce1a03c5d88f20e683eb7f2461794
https://doi.org/10.1210/clinem/dgac518
https://doi.org/10.1210/clinem/dgac518
Autor:
Erik A Imel, Francis H Glorieux, Michael P Whyte, Anthony A Portale, Craig F Munns, Ola Nilsson, Jill H Simmons, Raja Padidela, Noriyuki Namba, Hae Il Cheong, Pisit Pitukcheewanont, Etienne Sochett, Wolfgang Högler, Koji Muroya, Hiroyuki Tanaka, Gary S Gottesman, Andrew Biggin, Farzana Perwad, Angel Chen, Mary Scott Roberts, Leanne M Ward
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism.
Context In an open-label, randomized, controlled, phase 3 trial in 61 children aged 1 to 12 years with X-linked hypophosphatemia (XLH), burosumab improved rickets vs continuing conventional therapy with active vitamin D and phosphate. Objective We co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed138d999d811d037c85061f3e08ec9c
https://doi.org/10.1210/clinem/dgad230
https://doi.org/10.1210/clinem/dgad230
Autor:
Jennifer S. Yokoyama, Mina Matsuda-Abedini, Michelle R. Denburg, Juhi Kumar, Bradley A. Warady, Susan L. Furth, Stephen R. Hooper, Anthony A. Portale, Farzana Perwad
Publikováno v:
Kidney Medicine, Vol 2, Iss 4, Pp 398-406 (2020)
Rationale & Objective: Chronic kidney disease (CKD) in children is associated with cognitive dysfunction that affects school performance and quality of life. The relationship between CKD–mineral and bone disorder and cognitive function in children
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::56a23f49b17c7e30fce1456c1e95f17f
http://www.sciencedirect.com/science/article/pii/S259005952030100X
http://www.sciencedirect.com/science/article/pii/S259005952030100X
Autor:
Leanne M Ward, Francis H Glorieux, Michael P Whyte, Craig F Munns, Anthony A Portale, Wolfgang Högler, Jill H Simmons, Gary S Gottesman, Raja Padidela, Noriyuki Namba, Hae Il Cheong, Ola Nilsson, Meng Mao, Angel Chen, Alison Skrinar, Mary Scott Roberts, Erik A Imel
Publikováno v:
The Journal of clinical endocrinology and metabolism. 107(8)
Context Younger age at treatment onset with conventional therapy (phosphate salts and active vitamin D; Pi/D) is associated with improved growth and skeletal outcomes in children with X-linked hypophosphatemia (XLH). The effect of age on burosumab ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3833b9528dd71f24ad205d4bd938d40
https://pubmed.ncbi.nlm.nih.gov/35533340
https://pubmed.ncbi.nlm.nih.gov/35533340
Autor:
Mark R. Hanudel, Marciana L. Laster, Anthony A. Portale, Aditi Dokras, Raymond P. Quigley, German A. Lozano Guzman, Joshua J. Zaritsky, Nicole A. Hayde, Frederick J. Kaskel, Mark M. Mitsnefes, Jorge A. Ramirez, Peace D. Imani, Poyyapakkam R. Srivaths, Amy J. Kogon, Michelle R. Denburg, Tom D. Blydt-Hansen, Loretta Z. Reyes, Larry A. Greenbaum, Darcy K. Weidemann, Bradley A. Warady, David A. Elashoff, Susan R. Mendley, Tamara Isakova, Isidro B. Salusky
Publikováno v:
Pediatric nephrology (Berlin, Germany). 37(11)
Pediatric chronic kidney disease (CKD) is characterized by many co-morbidities, including impaired growth and development, CKD-mineral and bone disorder, anemia, dysregulated iron metabolism, and cardiovascular disease. In pediatric CKD cohorts, high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c42d4470695f449ebafe870a5cc132af
https://pubmed.ncbi.nlm.nih.gov/35237863
https://pubmed.ncbi.nlm.nih.gov/35237863
Autor:
Thomas Weber, Karl L. Insogna, Stuart H. Ralston, Farzana Perwad, Erik A. Imel, Mark Nixon, Hae Ii Cheong, Richard Eastell, Nobuaki Ito, Robin H. Lachmann, Suzanne M. Jan de Beur, Yasuo Imanishi, Angela Williams, Martine Cohen-Solal, Peter Kamenicky, Wei Sun, Annabel Nixon, Pisit Pitukcheewanont, Anthony A. Portale, Thomas O. Carpenter, Muhammad Javaid, Karine Briot, Hiroyuki Tanaka, Maria Luisa Brandi, Steven W. Ing, Rachel K Crowley, Takuo Kubota, Han Wook Yoo, Richard Keen, Yasuhiro Takeuchi
Publikováno v:
RMD Open, Vol 7, Iss 3 (2021)
RMD Open
RMD Open
ObjectivesTo report the impact of burosumab on patient-reported outcomes (PROs) and ambulatory function in adults with X-linked hypophosphataemia (XLH) through 96 weeks.MethodsAdults diagnosed with XLH were randomised 1:1 in a double-blinded trial to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63cd553f48f41260bba3c6ca756adb47
https://eprints.whiterose.ac.uk/178786/1/e001714.full.pdf
https://eprints.whiterose.ac.uk/178786/1/e001714.full.pdf
Autor:
Hae Il Cheong, Meng Mao, Ola Nilsson, Alison Skrinar, Gary S. Gottesman, Wolfgang Högler, Javier San Martin, Hiroyuki Tanaka, Noriyuki Namba, Raja Padidela, Francis H. Glorieux, Michael P. Whyte, Koji Muroya, Craig F Munns, Chao-Yin Chen, Andrew Biggin, Erik A. Imel, Etienne Sochett, Leanne Ward, Anthony A. Portale, Jill H. Simmons, Farzana Perwad, Pisit Pitukcheewanont
Publikováno v:
The Lancet. 393:2416-2427
X-linked hypophosphataemia in children is characterised by elevated serum concentrations of fibroblast growth factor 23 (FGF23), hypophosphataemia, rickets, lower extremity bowing, and growth impairment. We compared the efficacy and safety of continu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cefd2d3a00c5611970a49412fd42797f
https://doi.org/10.1016/s0140-6736(19)30654-3
https://doi.org/10.1016/s0140-6736(19)30654-3